Unicycive Therapeutics Inc

NASDAQ:UNCY   9:55:22 AM EDT
0.88
+0.08 (+10.44%)
Earnings Announcements

Unicycive Announces First Quarter Financial Results And Provides Business Update

Published: 05/12/2022 11:16 GMT
Unicycive Therapeutics Inc (UNCY) - Unicycive Announces First Quarter Financial Results and Provides Business Update.
Unicycive Therapeutics Inc- on Track to Initiate Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia in Healthy Volunteers in Q2 2022.
Unicycive Therapeutics Inc- Plans to Initiate Phase 1 Study for Uni-494 in Second Half of 2022.
Unicycive Therapeutics Inc - Qtrly Loss per Share $0.24.
Unicycive Therapeutics - As of Mar 31, Cash, Cash Equivalents Totaled $13.6 Million, Believes is Sufficient to Support It Through to Several Milestones.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.19

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.20

More details on our Analysts Page.